Li Zhu
About Li Zhu
Li Zhu is the Executive Director at Bristol Myers Squibb with over 17 years of experience in clinical pharmacology and pharmacometrics, particularly in hematology, oncology, and cell therapy.
Title
Li Zhu is currently the Executive Director at Bristol Myers Squibb.
Current Role at Bristol Myers Squibb
Li Zhu has been leading the Clinical Pharmacology and Pharmacometrics team in Hematology, Oncology, and Cell Therapy since July 2022. With extensive experience in these fields, Zhu plays a crucial role in guiding pharmacological strategies and therapies at Bristol Myers Squibb.
Previous Positions at Bristol Myers Squibb
Before becoming Executive Director, Li Zhu served as the Senior Director at Bristol Myers Squibb from 2020 to 2022, and prior to that as Director from 2017 to 2020, both in Princeton, New Jersey. These roles contributed to Zhu's extensive experience and leadership within the company.
Early Career in Pharmaceutical Industry
Li Zhu worked as a Senior Scientist at both ICON Development Solutions and Globomax from 2005 to 2006. During this period, Zhu built a solid foundation in clinical pharmacology and pharmacometrics, which paved the way for future roles.
Education and Expertise
Li Zhu achieved a Doctor of Philosophy (Ph.D.) in Pharmacokinetics from the University of Illinois Chicago, studying there from 1999 to 2005. Zhu also holds an MS in Pharmacy from the National University of Singapore (1997-1999) and a BS in Pharmacy from Shenyang Pharmaceutical University (1992-1997). This educational background underpins Zhu's extensive expertise in clinical pharmacology and pharmacometrics.